Staff Reports
Director of National Intelligence Tulsi Gabbard just dropped a stack of declassified slides that ought to make every American sit up. The ODNI deck, now public, ties U.S. funding and support to a global network of biological laboratories — more than 120 facilities in over 30 countries, with dozens marked in Ukraine alone. This is not hearsay on social media. It is an intelligence product with an approval stamp, and it changes the conversation from rumor to paperwork.
What the declassification actually shows
The slides name and map dozens of labs, flag several as high‑containment BSL‑3 facilities, and list stored pathogens ranging from anthrax and tularemia to Ebola, Marburg, MERS and SARS. Odessa and Kharkiv are called out by name; one Ukrainian veterinary institute is described as likely housing “dangerous pathogens” and vulnerable to seizure or damage. The ODNI statement says its review found more than 120 biolabs worldwide tied to longstanding U.S. funding and support.
Why this matters: oversight, risk, and gain‑of‑function concerns
For years the Pentagon’s Biological Threat Reduction Program worked with partners abroad to secure old Soviet collections and boost lab safety. That history is public and well documented. What’s new is internal intelligence, now declassified, showing pathogen holdings, biosafety problems at specific sites, and references to gain‑of‑function work in some projects. Intelligence slides are summaries, not lab notebooks, but they raise real questions: Who knew what, when, and why was public oversight so thin?
Don’t let the media spin shield the facts
Remember when anyone who raised alarms about foreign labs got accused of echoing enemy propaganda? That reflex was politically convenient then and embarrassing now. The ODNI materials do not automatically prove an offensive bioweapons program. But they do prove that more transparency was needed — yesterday. Officials who shrugged or scolded whistleblowers owe the public answers. If experimental work with dangerous pathogens was funded or overseen without clear public accounting and strong safeguards, that is a failure of both policy and trust.
What should happen next
Congress should hold prompt, public hearings. Independent biosafety experts must be allowed to inspect records and facilities. The intelligence community should release follow‑up batches with source context, and agencies must publish clear inventories of what was funded and what was being researched. Above all, we should demand an end to risky gain‑of‑function experiments unless they are transparently justified and tightly regulated. The public deserves neither secrecy nor spin when pathogens are involved.
Tulsi Gabbard deserves credit for putting these slides on the table. Whether she did it for politics or principle, the result is the same: more daylight. Now the hard work begins — sorting intelligence from inference, policy from partisanship, and real risk from reckless rhetoric. If leaders won’t act, citizens should insist they do. This isn’t a cable‑TV drama. It’s about real germs, real labs, and real safety. Time to treat it that way.
